BACKGROUND: The purpose of this study was to analyze long-term follow-up of a single institution's experience with a regimen of concomitant @entity900 / @entity1487 ( @entity1487 ) infusion and radiation given every other week. This analysis was stimulated by results of a randomized trial showing superiority for this regimen over induction @entity900 / @entity1487 chemotherapy followed by radiotherapy, especially in regional disease control. METHODS: All @entity1 with @entity5 who were referred by surgeons for nonoperative therapy and had a follow-up of at least 2 years were included. Concomitant chemoradiotherapy was administered days 1-5 of a 2-week treatment cycle, for a total of 7 cycles, with @entity900 60 mg/m2 day 1, @entity1487 800 mg/m2 given over 24 hours days 1-5, and radiation 2 Gy days 1-5. RESULTS: Seventy-eight @entity1 with stage III (n = 16) or IV (n = 62) were treated and followed for a median of 8 years. Six @entity1 died during treatment, of @entity1174 , @entity944 , @entity360 , and @entity64 . When assessed 6 weeks after the end of treatment, 45 @entity1 (63%) had no clinical evidence of disease, whereas 27 (37%) still had some persistent abnormality. However, 17 of these "partial responders" have not recurred. In all, 24 @entity1 (31%) have recurred or progressed, 13 at the primary site, 5 after 3 years. None of 16 stage III and 24 (39%) of 62 stage IV @entity1 ever progressed. Tongue and glottic larynx did best, with only 1 of 22 @entity1 ever failing (none locally). Supraglottic and oral @entity5 other than tongue had the worst failure rates. Nineteen @entity1 (24%) died of other causes ( @entity4420 ), @entity5 -free. @entity1 who @entity4420 correlated strongly with T stage (p < .002) but not with N stage or with AJC stage. The 5-year progression-free survival was 60% (confidence interval [CI] = 49% to 72%), and overall survival was 43% (CI = 33% to 56%). CONCLUSIONS: Disease control for this advanced @entity135 population was excellent. This regimen was especially effective in advanced @entity5 and all stage III disease sites. Advanced supraglottic and hypopharynx @entity5 are problematic. These, and especially @entity75 , are associated with high @entity4420 rates, possibly in part related to swallowing malfunction. Nevertheless, the long-term survival without surgical intervention was high with this regimen.

Concomitant @entity900 / @entity1487 infusion and radiotherapy in advanced XXXX : 8-year analysis of results.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity944 :: ('MESH:D003645', 'Disease') :: ['sudden death'] @entity5 :: ('MESH:D009369', 'Disease') :: ['stage III/IV disease', 'tumor', 'cavity cancers', 'cancers', 'tongue and glottic cancers'] @entity75 :: ('MESH:D001927', 'Disease') :: ['T4 lesions'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1174 :: ('MESH:D011015', 'Disease') :: ['aspiration pneumonia'] @entity360 :: ('MESH:D006471', 'Disease') :: ['gastrointestinal bleeding'] @entity4420 :: ('CHEBI:16973', 'Chemical') :: ['DOC'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-FU', 'fluorouracil']
@entity135 :: (MESH:D006258,Disease) :: ['head and neck cancer']
